• +41 91 682 20 40
  • info@elixi-int.com
  • Reserved Area
    • Login
    • Register
    • Request Document
    • Send Document
logo
  • Home
  • About Us
  • Services
  • Quality
  • News
  • Case Studies
  • Contact

Let's talk

info@yourwebsite.com
+1 (555) 123-4567

  • Search

Senza categoria

18 September 2020

New indication for Olumiant (baricitinib) as oral treatment for moderate to severe atopic dermatitis


by Elixi

29 August 2020

Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test


by Elixi

14 August 2020

Vaginal ring to reduce the risk of HIV infection for women in non-EU countries with high disease burden


by Elixi

14 August 2020

Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer


by Elixi

24 July 2020

Blenrep (belantamab mafodotin), new option for the treatment of relapsed and refractory multiple myeloma


by Elixi

14 July 2020

Inqovi (decitabine and cedazuridine), new Therapy for Myelodysplastic Syndromes (MDS) That Can Be Taken at Home


by Elixi

7 July 2020

Rukobia (fostemsavir), a new antiretroviral medication for patients who have run out of HIV treatment options


by Elixi

12 June 2020

Uplizna (inebilizumab-cdon)Therapy for Neuromyelitis Optica Spectrum Disorder Offers Patients Additional Treatment Option


by Elixi

6 June 2020

FDA Approves Merck’s RECARBRIO (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)


by Elixi

29 May 2020

FDA Approves Oriahnn (an estrogen and progestin combination product consisting of elagolix, estradiol and norethindrone acetate)to Treat Heavy Menstrual Bleeding Associated with Fibroids in Women


by Elixi

  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 13